The Department of Health made the submission, supported the evaluation, waived related cost recovery fees for itself, attended the PBAC meetings at which it has been considered and presumably participated in the discussion, wrote the outcome and managed the listing process. How is this not deeply problematic? …
A deeply problematic situation caused by officials making it up as they go
July 18, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
Georgia Forrest
New Stories
-
There is an ideology behind our funding systems, and it's the greatest barrier to change
March 11, 2026 - - Latest News -
New patient-led tool launched in Canberra to transform pain communication
March 10, 2026 - - Latest News -
Leader appointed to drive landmark Sydney biomedical hub toward global health breakthroughs
March 10, 2026 - -
New digital partnership expands access to clinical guidance for Australian healthcare professionals
March 10, 2026 - - Latest News -
Self injection option offers new flexibility for Australians living with Myasthenia Gravis
March 10, 2026 - - Latest News -
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News